Business Context and Reporting Period
This Form 8-K was filed by AcelRx Pharmaceuticals, Inc. on March 7, 2019. The filing serves as a current report to announce the commercial launch of the company's product, DSUVIA, and to reference the press release containing financial results for the fourth quarter and full year ended December 31, 2018.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1) but are not detailed in the body of this 8-K filing.
Material Changes
- Product Launch: The company announced the commercial launch of DSUVIA.
- Financial Reporting: The filing references the release of Fourth Quarter and Full Year 2018 financial results, though specific comparative figures are not included in this text.
Guidance, Outlook, and Risks
The filing includes a standard legal disclaimer stating that the information furnished in Item 2.02 is not "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into any other SEC filings. No specific forward-looking guidance, risk factors, or management commentary regarding future performance is detailed in the text of this document.
Investor Verification Checklist
- Review Exhibit 99.1 (the press release) for specific Q4 and Full Year 2018 financial figures (revenue, net loss, cash position).
- Verify the commercial status and initial market reception of the newly launched product, DSUVIA.
- Confirm the company's cash runway and liquidity position as of December 31, 2018, to assess operational sustainability.